266 related articles for article (PubMed ID: 19165664)
1. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial.
Galindo A; Bodri D; Guillén JJ; Colodrón M; Vernaeve V; Coll O
Gynecol Endocrinol; 2009 Jan; 25(1):60-6. PubMed ID: 19165664
[TBL] [Abstract][Full Text] [Related]
2. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
Youssef MA; Van der Veen F; Al-Inany HG; Mochtar MH; Griesinger G; Nagi Mohesen M; Aboulfoutouh I; van Wely M
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD008046. PubMed ID: 25358904
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; Aboulfoutouh I; Khattab SM; van Wely M
Cochrane Database Syst Rev; 2011 Jan; (1):CD008046. PubMed ID: 21249699
[TBL] [Abstract][Full Text] [Related]
5. Comparison between a GnRH antagonist and a GnRH agonist flare-up protocol in oocyte donors: a randomized clinical trial.
Bodri D; Vernaeve V; Guillén JJ; Vidal R; Figueras F; Coll O
Hum Reprod; 2006 Sep; 21(9):2246-51. PubMed ID: 16704995
[TBL] [Abstract][Full Text] [Related]
6. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; van Wely M
Cochrane Database Syst Rev; 2010 Nov; (11):CD008046. PubMed ID: 21069701
[TBL] [Abstract][Full Text] [Related]
8. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
[TBL] [Abstract][Full Text] [Related]
9. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
[TBL] [Abstract][Full Text] [Related]
10. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
[TBL] [Abstract][Full Text] [Related]
11. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
12. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study.
Melo M; Busso CE; Bellver J; Alama P; Garrido N; Meseguer M; Pellicer A; Remohí J
Reprod Biomed Online; 2009 Oct; 19(4):486-92. PubMed ID: 19909588
[TBL] [Abstract][Full Text] [Related]
13. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
[TBL] [Abstract][Full Text] [Related]
14. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
Kolibianakis EM; Schultze-Mosgau A; Schroer A; van Steirteghem A; Devroey P; Diedrich K; Griesinger G
Hum Reprod; 2005 Oct; 20(10):2887-92. PubMed ID: 15979994
[TBL] [Abstract][Full Text] [Related]
15. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
[TBL] [Abstract][Full Text] [Related]
16. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
[TBL] [Abstract][Full Text] [Related]
17. [Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation].
Kdous M; Chaker A; Bouyahia M; Zhioua F; Zhioua A
Tunis Med; 2009 Dec; 87(12):834-42. PubMed ID: 20209851
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone agonist or human chorionic gonadotropin for final oocyte maturation in an oocyte donor program.
Erb TM; Vitek W; Wakim AN
Fertil Steril; 2010 Feb; 93(2):374-8. PubMed ID: 19171336
[TBL] [Abstract][Full Text] [Related]
19. Triggering with GnRH agonist in oocyte-donation cycles: oestradiol monitoring is not necessary during ovarian stimulation.
Castillo JC; Dolz M; Moreno J; Gijón L; Ferrer R; Ferrero E; Bonilla-Musoles F
Reprod Biomed Online; 2012 Feb; 24(2):247-50. PubMed ID: 22196891
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol.
Koichi K; Yukiko N; Shima K; Sachiko S
J Assist Reprod Genet; 2006 May; 23(5):223-8. PubMed ID: 16786420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
